Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus

Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus

Abstract Objective To compare the efficacy and safety of the once-daily prandial glucagon-like peptide-1 receptor agonist lixisenatide with the dipeptidyl peptidase-4 inhibitor sitagliptin in patients aged

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical & translational endocrinology 2014-06, Vol.1 (2), p.31-37
Hauptverfasser: Van Gaal, Luc, Souhami, Elisabeth, Zhou, Tianyue, Aronson, Ronnie
Format: Artikel
Sprache:eng
Schlagworte:
Body weight
Endocrinology & Metabolism
Glycated hemoglobin (HbA1c)
Postprandial plasma glucose (PPG)
Research Paper
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Objective To compare the efficacy and safety of the once-daily prandial glucagon-like peptide-1 receptor agonist lixisenatide with the dipeptidyl peptidase-4 inhibitor sitagliptin in patients aged
ISSN:2214-6237
2214-6237
DOI:10.1016/j.jcte.2014.03.001